- Novo Nordisk's investigational anti-inflammatory drug ziltivekimab did not reduce the risk of major heart events in a Phase 3 trial involving over 6,300 patients.
- Although ziltivekimab lowered inflammation markers, it did not translate into a reduction in cardiovascular-related death, heart attack, or stroke.
- Novo Nordisk shares dropped about 7% following the announcement.
- The article is exclusive to STAT+ subscribers.